Review article: The management of primary sclerosing cholangitis

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 1, 1997, Pages 33-43

  Mitchell, S A ^a   Chapman, R W G ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOSPORIN A; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; PREDNISONE; TACROLIMUS; URSODEOXYCHOLIC ACID;

BILE DUCT CARCINOMA; CHOLESTASIS; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SCLEROSING CHOLANGITIS;

EID: 0031031552     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.91263000.x     Document Type: Review

References (65)

1. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-7.
2. Lo SK, Fleming KA, Chapman RW. Prevalence of antineutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut 1992; 33: 1370-5.
3. Chapman R, Does HLA status influence prognosis in primary sclerosing cholangitis? Gastroenterology 1995; 108: 937-40.
4. Martins E, Graham AK, Chapman RW, Fleming KA. Elevation of gammadelta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases. Hepatology 1996; 23: 988-93.
5. Pokorny CS, McCaughan GW, Gallagher ND, Selby WS. Sclerosing cholangitis and biliary tract calculi - primary or secondary? Gut 1992; 33: 1376-80.
6. Broome U, Glaumann H, Hellers G, et al. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994; 35: 84-9.
7. Garden JM, Ostrow JD, Roenigk H Jr. Pruritus in hepatic cholestasis. Pathogenesis and therapy. Arch Dermatol 1985; 121: 1415-20.
8. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br Med J 1988; 297 (6662): 1501-4.
9. Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritis of chronic liver disease. Am J Gastroenterol 1996; 91: 1022-3.
10. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61: 33-7.
11. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; i (8638): 574-6.
12. Jorgensen RA, Lindor KD, Sartin JS. LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995; 20: 215-9.
13. Munoz SJ, Heubi, JE, Balistreri WF, Maddrey WC, Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology 1989; 9: 525-31.
14. Hay JE, Lindor KD, Wiesner RH, et al. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14: 257-61.
15. Broome U, Lofberg R, Veress B, Eriksso LS. Primary sclerosing cholangitis and ulcerative colitis. Evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-8.
16. Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110: 331-8.
17. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-9.
18. Mirza DF, Davies M, Olliff S, et al. Preoperative diagnosis of cholangiocarcinoma in primary sclerosing cholangitis in potential liver transplantation candidates. Hepatology 1994; 20: 154A (Abstract).
19. Ferrari-Junior AP, Lichtenstein DR, Slivka A, Chang C. Carr-Locke DL. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc 1994; 40 (2 Part 1): 140-5.
20. Lee JG, Leung JW, Baillie J, Layfield LJ, Cotton PB. Benign, dyplasitic or malignant - making sense of endoscopic bile duct brush cytology: results in 149 consecutive patients. Am J Gastroenterol 1995; 90: 722-6.
21. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumour markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865-9.
22. Myburgh JA. Surgical biliary drainage in primary sclerosing cholangitis. The role of the Hepp-Couinaud approach. Arch Surg 1994; 129: 1057-62.
23. Lee JC, Schutz SM, England RE, Leung JW, Cotton PB. Endoscopic therapy of sclerosing cholangitis. Hepatology 1995; 21: 661-7.
24. LaRusso NF, Wiesner RH, Ludwig J, et al. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95: 1036-42.
25. Sivak M Jr, Farmer RG, Lalli AF. Sclerosing cholangitis: its increasing frequency of recognition and association with inflammatory bowel disease. J Clin Gastroenterol 1981; 3: 261-6.
26. Burgert SL, Brown BP, Kirkpatrick RB, LaBrecque DR. Positive corticosteroid response in early primary sclerosing cholangitis. Gastroenterology 1984; 86: 1037. (Abstract.)
27. Lindor KD, Wiesner RH, Colwell LJ, et al. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991; 86: 57-61.
28. Grijm R, Huibregtse K, Bartelsman J, et al. Therapeutic investigations in primary sclerosing cholangitis. Dig Dis Sci 1986; 31: 792-8.
29. Jeffrey GP, Reed WD, Laurence BH, Shilkin KB. Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases. J Gastroenterol Hepatol 1990; 5: 135-40.
30. Craig PI, Williams SJ, Hatfield ARW, Ng M, Cotton PB. Endoscopic management of primary sclerosing cholangitis. Gut 1990; 31: 1182a. (Abstract.)
31. Allison MC, Burroughs AK, Noone P, Summerfield JA. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical. cholangiographic and bacteriological study. J Hepatol 1986; 3: 118-22.
32. Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991; 86: 546-52.
33. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106: 494-9.
34. Lindor KD, Jorgensen RA, Anderson ML, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study. Am J Gastroenterol 1996; 91: 511-5.
35. Javett SL. Azathioprine in primary sclerosing cholangitis. Lancet 1971; i: 810-1.
36. Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971; ii (725): 663-4.
37. Wiesner RH, Steiner B, LaRusso NF, Lindor KD, Baldus WP. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis. Hepatology 1991; 14: 63A. (Abstract.)
38. Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993; 34: 242-6.
39. Kyokane K, Ichihara T, Horisawa M, et al. Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology 1994; 41: 449-52.
40. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 455-9.
41. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995; 108: 1199-203.
42. Jazrawi RP, de-Caestecker JS, Goggin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106: 134-42.
43. Fisher MM, Paradine ME. Influence of ursodeoxycholic acid on biochemical parameters in cholestatic liver disease. Gastroenterology 1986; 90: 1725 (Abstract).
44. Stiehl A, Raedsch R, Kommerell B. The effect of ursodeoxycholic acid in primary sclerosing cholangitis. A comparison to primary biliary cirrhosis. Gastroenterology 1988; 94: A595. (Abstract.)
45. Podda M, Ghezzi C, Battezzati PM, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989; 34 (Suppl. 12): 59S-65S.
46. Stiehl A, Raedsch R, Rudolph G, Theilmann L. Treatment of primary sclerosing cholangitis with Ursodeoxycholic acid: first results of a controlled study. Hepatology 1989; 10: A602. (Abstract.)
47. Chazouilleres O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11: 120-3.
48. O'Brien CB, Senior JB, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991; 14: 838-47.
49. O'Brien S, Craig PI, Hatfield ARW. The effect of ursodeoxycholic acid treatment in primary sclerosing cholangitis - results of a pilot study. Gastroenterology 1993; 104: A966. (Abstract.)
50. van Milligen de Wit M, van Deventer SJH, van Bracht J, Rauws EAJ. Ursodeoxycholic acid in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1995; 7: A181 (Abstract).
51. Stiehl A, Benz C, Rudolph G, et al. Effect of ursodeoxycholic acid and of endoscopic dilation on survival in PSC. Final results of an 8 year prospective study. Gastroenterology 1996; 110 (Suppl. 4): A1334. (Abstract.)
52. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16: 707-14.
53. Lo SK, Hermann R, Chapman RW, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: a double-blind placebo controlled trial. Hepatology 1992; 16: 92A. (Abstract.)
54. Van Thiel DH, Wright HI, Gavaler JS. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: preliminary report of a randomized controlled trial. Hepatology 1992; 16 (2 Part 2): 62A. (Abstract.)
55. Stiehl A, Walker S, Stiehl L, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20: 57-64.
56. Bansi D, Christie J, Fleming K, Chapman R. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a randomised double-blind placebo-controlled trial. Gastroenterology 1996; 110 (Suppl. 4): A1146. (Abstract.)
57. van Hoogstraten HJF, Wolfhagen FJH, van de Meeberg PC, et al. Single versus three times daily ursodeoxycholic acid for primary sclerosing cholangitis: results of a randomized controlled trial. Gastroenterology 1996; 110 (Suppl. 4): A1352. (Abstract.)
58. Lindor KD, The Mayo PSC/UDCA Study Group. A randomized trial of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Gastroenterology 1996; 110 (Suppl. 4): A1252. (Abstract.)
59. Olsson R, Hagerstrand I, Broome U, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995; 48: 933-5.
60. Harrison J, McMaster P. The role of orthotopic liver transplantation in the management of sclerosing cholangitis. Hepatology 1994; 20 (1 Part 2): 14S-19S.
61. Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22: 451-7.
62. Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995; 117: 146-55.
63. Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 1994; 20: 356-61.
64. Nashan B, Schlitt HJ, Tusch G, et al. Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation. Hepatology 1996; 22: 1105-11.
65. Scapa E, Orda R. Primary sclerosing cholangitis and tamoxifen. Int Hepatol Commun 1995; 4: 149-52.